secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2022-07-06T23:59:59+00:00
Accession:  0001558370-22-010548
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio appoints Dr. Michael Kamarck as Class I director
------------------------------------------------------------

- Dr. Kamarck appointed to board and Governance Committee, effective July 2, 2022.
- He is Chairman of Sanofi Biotech Advisory Council and former CTO at Vir Biotechnology.
- Received options to purchase 48,000 shares vesting over 36 months; cash per director policy.
- Background includes ~30 years leadership at Merck, Wyeth, and Bayer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837022010548/0001558370-22-010548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837022010548/pasg-20220702x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-010548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer